Combined point mutations in codon 12 and 13 of KRAS oncogene in prostate carcinomas.
about
Silencing KRAS overexpression in arsenic-transformed prostate epithelial and stem cells partially mitigates malignant phenotype.Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells.Aberrant microRNA expression likely controls RAS oncogene activation during malignant transformation of human prostate epithelial and stem cells by arsenic.Silencing KRAS Overexpression in Cadmium-Transformed Prostate Epithelial Cells Mitigates Malignant Phenotype
P2860
Combined point mutations in codon 12 and 13 of KRAS oncogene in prostate carcinomas.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Combined point mutations in codon 12 and 13 of KRAS oncogene in prostate carcinomas.
@en
Combined point mutations in codon 12 and 13 of KRAS oncogene in prostate carcinomas.
@nl
type
label
Combined point mutations in codon 12 and 13 of KRAS oncogene in prostate carcinomas.
@en
Combined point mutations in codon 12 and 13 of KRAS oncogene in prostate carcinomas.
@nl
prefLabel
Combined point mutations in codon 12 and 13 of KRAS oncogene in prostate carcinomas.
@en
Combined point mutations in codon 12 and 13 of KRAS oncogene in prostate carcinomas.
@nl
P2093
P2860
P1476
Combined point mutations in codon 12 and 13 of KRAS oncogene in prostate carcinomas.
@en
P2093
Ahmet Uludag
Cabir Alan
Davran Kilinc
Fatma Silan
Fazilet Yildiz
Ozturk Ozdemir
Sinem Atik
Yener Gultekin
P2860
P2888
P304
P356
10.1007/S11033-011-0898-8
P577
2011-05-24T00:00:00Z